These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16175357)

  • 1. Cytomegalovirus cholangitis presenting with recurrent hemobilia.
    Tleyjeh IM; Georgescu G; Virk A; Barajas ED; Mirzoyev Z; Anavekar N; Baddour LM
    Eur J Clin Microbiol Infect Dis; 2005 Sep; 24(9):634-6. PubMed ID: 16175357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemobilia caused by cytomegalovirus cholangiopathy.
    Prasad GA; Abraham SC; Baron TH; Topazian MD
    Am J Gastroenterol; 2005 Nov; 100(11):2592-5. PubMed ID: 16279917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe cytomegalovirus infection in a second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi-organ failure with fatal outcome: a case report.
    Miszewska-Szyszkowska D; Mikołajczyk N; Komuda-Leszek E; Wieczorek-Godlewska R; Świder R; Dęborska-Materkowska D; Szmidt J; Durlik M
    Ann Transplant; 2015 Mar; 20():169-74. PubMed ID: 25813912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral escape and T-cell immunity during ganciclovir treatment of cytomegalovirus infection: case report of a pancreatico-renal transplant recipient.
    Benz C; Holz G; Michel D; Awerkiew S; Dries V; Stippel D; Goeser T; Busch DH
    Transplantation; 2003 Mar; 75(5):724-7. PubMed ID: 12640316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatitis and cholangitis due to cytomegalovirus in a patient with hyperimmunoglobulin E syndrome.
    Watanabe T; Joko K; Yokota T; Kobayashi Y; Oono Y; Takechi S; Ooshiro Y; Abe M; Murakami H; Matsuura B; Hiasa Y; Onji M
    Pancreas; 2010 Aug; 39(6):940-2. PubMed ID: 20664484
    [No Abstract]   [Full Text] [Related]  

  • 6. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
    Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients.
    Nafar M; Roshan A; Pour-Reza-Gholi F; Samadian F; Ahmadpoor P; Samavat S; Abbasi MA
    Iran J Kidney Dis; 2014 May; 8(3):231-5. PubMed ID: 24878947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
    Mylonakis E; Kallas WM; Fishman JA
    Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
    Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients.
    Limaye AP
    Semin Respir Infect; 2002 Dec; 17(4):265-73. PubMed ID: 12497543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.
    Deback C; Burrel S; Varnous S; Carcelain G; Conan F; Aït-Arkoub Z; Autran B; Gandjbakhch I; Agut H; Boutolleau D
    Antivir Ther; 2015; 20(2):249-54. PubMed ID: 25219330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unusual presentation of cytomegalovirus infection in patients after organ transplant.
    Tiple A; Kamar N; Esposito L; Mengelle C; Combelles S; Otal P; Celine Guilbeau-Frugier C; Rostaing L
    Exp Clin Transplant; 2009 Mar; 7(1):45-9. PubMed ID: 19364312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Should recurrent Cytomegalovirus infections in patients with liver transplantation be treated?].
    Tarp BD; Astrup LB
    Ugeskr Laeger; 1997 May; 159(22):3413-6. PubMed ID: 9199030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
    Mwintshi K; Brennan DC
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease.
    Humar A; Kumar D; Boivin G; Caliendo AM
    J Infect Dis; 2002 Sep; 186(6):829-33. PubMed ID: 12198618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
    Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
    Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
    PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.